Tag: Pharmaceutical Research Award

Antra Chaudhary | Pharmaceutical Science | Young Scientist Award

Published on by World Science Awards

Young Scientist Award

Antra Chaudhary,
Jamia Hamdard University, New Delhi, India.

Antra Chaudhary
Affiliation Jamia Hamdard University
Country India
Scopus ID 57406830100
Documents 10
Citations 119
h-index 5
Subject Area Pharmacology, Toxicology and Pharmaceutical Science
Event World Science Awards
ORCID 0009-0006-9003-5566

Antra Chaudhary is an Indian pharmacology researcher and doctoral scholar recognized for her contributions to bone pharmacology, oxidative stress, inflammatory disorders, and neuroprotection research. Her academic work has focused extensively on translational pharmacological approaches involving medicinal plants, osteoporosis therapeutics, neuroinflammation, stem cell-based therapies, and molecular signaling pathways associated with disease progression and tissue protection.[1] She is currently pursuing doctoral research at Jamia Hamdard University under the supervision of Prof. Divya Vohora, where her investigations explore the therapeutic potential of natural compounds against glucocorticoid-induced bone damage and postmenopausal osteoporosis.[2]

Abstract

This academic article presents a scholarly overview of the research contributions, scientific achievements, and professional development of Antra Chaudhary, a pharmacology researcher specializing in bone pharmacology, oxidative stress, inflammatory disorders, and neuroprotection. Her research has contributed to understanding molecular signaling pathways associated with osteoporosis, ischemic stroke, rheumatoid arthritis, and mitochondrial dysfunction. Through interdisciplinary pharmacological investigations involving in vitro and in vivo models, her work has emphasized translational therapeutic strategies and the use of bioactive compounds for disease modulation.[3] The article further documents her academic qualifications, awards, technical expertise, scientific publications, and suitability for academic recognition in the field of pharmacology and biomedical sciences.

Keywords

Bone Pharmacology, Oxidative Stress, Osteoporosis, Pharmacology, Neuroprotection, Medicinal Plants, Inflammatory Diseases, Stem Cell Therapy, Molecular Pharmacology, Translational Research, Rheumatoid Arthritis, Glucocorticoid-Induced Bone Damage, Pharmacodynamics, Biomedical Sciences.

Introduction

Contemporary pharmacological research increasingly emphasizes translational approaches that integrate molecular biology, therapeutic intervention, and clinical applicability. Researchers in pharmacology are actively investigating novel compounds and signaling pathways to address chronic diseases, neurodegeneration, inflammatory disorders, and metabolic dysfunctions.[4] Within this scientific landscape, Antra Chaudhary has contributed to emerging research areas involving osteoporosis therapeutics, oxidative stress modulation, neuroinflammation, and medicinal plant-based pharmacological interventions.

Her academic journey reflects a progression through pharmaceutical sciences and toxicology training, supported by competitive national examinations including GPAT and NIPER-JEE. She has participated in multidisciplinary research projects and advanced laboratory investigations utilizing molecular, histological, and imaging-based techniques for experimental pharmacology studies.[5]

Research Profile

Antra Chaudhary completed her Master of Science in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, where she worked on medicinal plant extracts from North-East India for inflammatory disease research. Her doctoral research at Jamia Hamdard University focuses on bone pharmacology and oxidative stress biology under the supervision of Prof. Divya Vohora.[2]

Her technical expertise encompasses a broad range of experimental methodologies, including Western blotting, RT-PCR, immunohistochemistry, fluorescence microscopy, micro-computed tomography, small animal imaging, and cell culture systems. She has also demonstrated competence in pharmacological data analysis using GraphPad Prism and image analysis software.[3]

  • DST WISE KIRAN Fellow for doctoral research in Life Sciences.
  • Qualified GPAT and NIPER-JEE examinations with competitive national rankings.
  • Recipient of the Young Investigator Award 2025 at IPC-IPSCON 2025.
  • Contributor to peer-reviewed journals in pharmacology and neuroscience.

Research Contributions

The scientific contributions of Antra Chaudhary span multiple pharmacological domains, including neuroprotection, osteoporosis, inflammatory signaling, and mitochondrial biology. Her collaborative studies have investigated the role of cardiolipin-mediated mitochondrial protection in ischemic stroke and the therapeutic implications of stem cell-mediated inflammasome modulation.[1]

Her work on bone-targeted daidzein-loaded hydroxyapatite nanoparticles evaluated osteogenic potential and pharmacodynamic activity in postmenopausal osteoporosis models, highlighting nanotechnology-assisted therapeutic delivery systems.[8] Additionally, she contributed to research exploring TLR4/NF-κB and Keap1/Nrf2 signaling pathways in rheumatoid arthritis using perillyl alcohol interventions.[2]

Her review publications further discuss CRISPR/Cas9 technologies in neurological disorders, drug repurposing strategies for stroke intervention, and glial cell responses in neurodegenerative conditions.[5]

Publications

Selected Research Articles

  1. Gautam N, Sharma P, Chaudhary A, et al. Investigating the osteogenic potential of bone-targeted daidzein loaded hydroxyapatite nanoparticles for postmenopausal osteoporosis. Journal of Drug Targeting, 2025.
  2. Sarmah D, Sarkar A, Datta A, et al. Cardiolipin-mediated alleviation of mitochondrial dysfunction is a neuroprotective effect of statin in ischemic stroke. ACS Chemical Neuroscience, 2023.
  3. Puppala ER, Jain S, Saha P, et al. Perillyl alcohol attenuates rheumatoid arthritis via regulating TLR4/NF-κB and Keap1/Nrf2 signaling pathways. Phytomedicine, 2022.

Review Articles

  • Advancement in CRISPR/Cas9 technology to better understand and treat neurological disorders.
  • Drug repurposing for stroke intervention.
  • Glial cells response in stroke.

Research Impact

The research contributions of Antra Chaudhary demonstrate interdisciplinary relevance across pharmacology, neuroscience, and biomedical sciences. Her publications address clinically significant challenges associated with osteoporosis, ischemic stroke, inflammatory diseases, and oxidative stress-mediated tissue injury.[11]

Her collaborative work in molecular pharmacology and translational therapeutics contributes to ongoing scientific efforts aimed at developing safer and more effective treatment strategies. The integration of medicinal plant research, nanotechnology-based drug delivery systems, and cellular signaling investigations highlights the translational significance of her scientific profile.[2]

Award Suitability

Antra Chaudhary’s academic profile reflects sustained engagement in experimental pharmacology, translational biomedical research, and scientific dissemination through peer-reviewed publications and conference presentations. Her recognition through the Young Investigator Award at IPC-IPSCON 2025 further demonstrates professional acknowledgment of her contributions within the pharmacological research community.[3]

Her expertise in advanced laboratory techniques, coupled with her publication record and participation in international scientific activities, supports her suitability for academic recognition in the field of pharmacology and bone research. The interdisciplinary scope of her work aligns with contemporary priorities in therapeutic innovation and disease prevention.

Conclusion

Antra Chaudhary represents an emerging researcher in pharmacology whose scientific activities encompass bone pharmacology, oxidative stress biology, neuroprotection, and translational therapeutics. Through experimental research, scholarly publications, and active participation in scientific conferences, she has contributed to advancing knowledge in multiple biomedical domains. Her work continues to support the development of innovative therapeutic approaches aimed at improving disease management and bone health outcomes.[1]

References

  1. Jamia Hamdard University. (2026). Doctoral Research Profile of Antra Chaudhary.
  2. Jamia Hamdard University. (2026). Bone Pharmacology and Oxidative Stress Research Program.
  3. Elsevier. (2025). Pharmacological approaches in osteoporosis and translational therapeutics.
  4. Drug Discovery Today. (2022). Drug repurposing for stroke intervention.
    https://doi.org/10.1016/j.drudis.2022.03.014
  5. National Institute of Pharmaceutical Education and Research. (2020). MS Research Project Documentation.

Mohmmad Younus Wani | Medicinal Chemistry | Excellence in Research Award

Published on by World Science Awards

Assoc. Prof. Dr. Mohmmad Younus Wani | Medicinal Chemistry | Excellence in Research Award

University of Jeddah, Saudi Arabia

Assoc. Prof. Dr. Mohmmad Younus Wani is an accomplished Associate Professor at the University of Jeddah, specializing in medicinal and organic chemistry with a strong focus on drug discovery and antimicrobial resistance. His research centers on the development of small molecule inhibitors and innovative therapeutic strategies to combat drug-resistant pathogens and hospital-acquired infections. With over 90 high-impact publications, an h-index of 33, and more than 4,100 citations, he has established a significant global research presence. Dr. Wani has secured multiple competitive research grants, including major funded projects as Principal Investigator, and holds several US patents in antifungal therapeutics. He has extensive international research experience, having worked in the United States, Portugal, and India, and actively collaborates across multidisciplinary teams. His work contributes to advancing healthcare solutions and addressing critical global challenges in infectious diseases and antimicrobial resistance.

Citation Metrics (Scopus)

3500
2500
1500
500

Citations
3,152

h-index
29

Documents
92

Citations

h-index

Documents

Featured Publications

MA Malik, MY Wani, MA Hashim (2012).
Microemulsion method: A novel route to synthesize organic and inorganic nanomaterials: 1st Nano Update
Arabian Journal of Chemistry | Journal Article · 2012 · 📊 Citations: 864

MA Malik, OA Dar, P Gull, MY Wani, AA Hashmi (2018).
Heterocyclic Schiff base transition metal complexes in antimicrobial and anticancer chemotherapy
MedChemComm | Journal Article · 2018 · 📊 Citations: 459

S Kumar, MY Wani, CT Arranja, JA e Silva, B Avula, AJFN Sobral (2015).
Porphyrins as nanoreactors in the carbon dioxide capture and conversion: a review
Journal of Materials Chemistry A | Journal Article · 2015 · 📊 Citations: 161

MA Malik, MY Wani, SA Al-Thabaiti, RA Shiekh (2014).
Tetrazoles as carboxylic acid isosteres: chemistry and biology
Journal of Inclusion Phenomena and Macrocyclic Chemistry | Journal Article · 2014 · 📊 Citations: 161

MY Wani, MA Hashim, F Nabi, MA Malik (2011).
Nanotoxicity: dimensional and morphological concerns
Advances in Physical Chemistry | Journal Article · 2011 · 📊 Citations: 136

Yan Niu | Pharmaceutical Science | Research Excellence Award

Published on by World Science Awards

Prof. Yan Niu | Pharmaceutical Science | Research Excellence Award

Peking University | China

Prof. Yan Niu is a medicinal chemist at Peking University whose research focuses on the discovery and optimization of biologically active small molecules, with special emphasis on hydrophobic tagging–based targeted protein degradation. She has contributed significant advances in amino-acid–derived hydrophobic tags capable of inducing selective POI degradation with mechanisms and pharmacological profiles distinct from PROTACs, expanding the chemical space available for next-generation degraders. With 47 Scopus-indexed publications, 549 citations, and an h-index of 14, her work bridges synthetic chemistry, chemical biology, and drug discovery. She has led competitive national projects, filed three patents, and collaborated internationally in Germany and Austria. Her research provides promising strategies for developing novel therapeutics and deepens mechanistic understanding of protein degradation pathways, contributing to innovation in medicinal chemistry and early-stage drug development.

Citation Metrics (Scopus)

500
450
300
150
0

Citations
549
Documents
47
h-index
14

Citations

Documents

h-index

Featured Publications

 

Jiunn-Liang Ko | Pharmaceutical Science | Research Excellence Award

Published on by World Science Awards

Prof. Jiunn-Liang Ko | Pharmaceutical Science | Research Excellence Award

Chung Shan Medical University | Taiwan

Dr. Jiunn-Liang Ko is a distinguished scholar in the fields of biochemistry, toxicology, and medical sciences, with a research career spanning more than three decades. He earned his Ph.D. in Biochemistry from the College of Medicine at National Taiwan University (1995), following a Master’s and Bachelor’s degree in Biology from Fu-Jen University. His academic and scientific journey reflects unwavering dedication to advancing biomedical research, particularly in molecular toxicology, environmental health, and translational medicine. Dr. Ko began his professional research career as a Postdoctoral Fellow at the Taiwan Agricultural Chemicals and Toxic Substances Research Institute, where he contributed to pioneering work in biopesticide safety and toxicological mechanisms. In 2003, he joined Chung-Shan Medical University, where he progressed from Professor in the Institute of Toxicology to Director of multiple strategic units, including the Research & Development Office, the Instrumental Center, and the Institute of Medical and Molecular Toxicology. His leadership has been instrumental in enhancing interdisciplinary research capacity, laboratory infrastructure, and academic excellence at the institution. Since 2011, Dr. Ko has served as Professor at the Institute of Medicine at Chung-Shan Medical University, continuing to lead high-impact research, mentor scholars, and foster international collaborations. His work encompasses molecular carcinogenesis, toxicogenomics, and the cellular responses to environmental hazards, positioning him as a key contributor to advancing understanding of public health risks and disease prevention. Over his career, he has authored numerous peer-reviewed publications, contributed to national and international projects, and collaborated across academia, healthcare, and applied science sectors. His research outputs are recognized for their scientific rigor and real-world relevance, influencing policy, clinical practice, and biosafety standards. Through his sustained academic leadership, scientific innovation, and commitment to education, Dr. Jiunn-Liang Ko continues to contribute significantly to global biomedical research and the advancement of public health.

Profiles: Scopus | ORCID | Google Scholar

Featured Publications

Yang, Y.-T., Hsu, C.-H., Wang, Y.-F., Chang, Y.-J., Yang, H.-J., Ko, J.-L., & Yang, K.-C. (2022). Worsening quality of life in young adult, highly educated, and married female patients with vitiligo: A hospital-based case control study in Taiwan. International Journal of Environmental Research and Public Health, 19(11), 6741.

Chang, J.-C., Chiou, J.-Y., Ko, J.-L., Huang, J.-Y., & Lue, K.-H. (2021). Early bronchiolitis contributes to preschool asthma. Children, 8(12), 1176.

Hsin, I.-L., Shen, H.-P., Chang, H.-Y., Ko, J.-L., & Wang, P.-H. (2021). Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 positive feedback loop induces cell cycle arrest by dual PI3K/mTOR inhibitor PQR309 in endometrial cancer cell lines. Cells, 10(11), 2916.

Hsiao, Y.-P., Chen, H.-L., Tsai, J.-N., Lin, M.-Y., Liao, J.-W., Wei, M.-S., Ko, J.-L., & Ou, C.-C. (2021). Administration of Lactobacillus reuteri combined with Clostridium butyricum attenuates cisplatin-induced renal damage by gut microbiota reconstitution, increasing butyric acid production, and suppressing renal inflammation. Nutrients, 13(8), 2792.

Wu, S.-W., Ko, J.-L., Liu, B.-H., & Yu, F.-Y. (2020). A sensitive two-analyte immunochromatographic strip for simultaneously detecting aflatoxin M1 and chloramphenicol in milk. Toxins, 12(10), 637.

Omid Mehrpour | Pharmaceutical Science | Editorial Board Member

Published on by World Science Awards

Dr. Omid Mehrpour | Pharmaceutical Science | Editorial Board Member

Wayne State University | United States

Dr. Omid Mehrpour is a distinguished medical toxicologist, clinical data scientist, and physician whose work integrates toxicology, public health, and artificial intelligence to advance diagnostic accuracy and patient outcomes. With over two decades of academic, clinical, and research experience, he has become an internationally recognized expert in poisoning, substance use disorders, and AI-driven medical decision-making. Dr. Mehrpour has authored more than 200 peer-reviewed articles, ten book chapters, and a book translation, accumulating over 4,000 scientific citations. His publications and research outputs have significantly shaped clinical toxicology guidelines globally, particularly in areas related to opioids, heavy metals, aluminum phosphide, cannabinoids, and environmental toxicants. A pioneer in AI-based diagnostic innovation, Dr. Mehrpour developed machine learning–driven protocols for poison diagnosis, leading to two registered U.S. patents and additional patents in Iran for diagnostic software and toxicology devices. His work at the Rocky Mountain Poison & Drug Safety Center and collaborations with national databases such as NPDS and ToxIC contributed foundational methods for rapid identification and triage of poisoning cases. He has also led AI and clinical informatics initiatives at the University of Colorado Anschutz Medical Campus and founded AI and Health LLC to develop intelligent clinical tools that enhance diagnosis and care delivery. Throughout his career, Dr. Mehrpour has held leadership roles including Head of the Medical Toxicology and Drug Abuse Research Center and Director of the Poisoning Ward at Birjand University of Medical Sciences. He has supervised numerous graduate researchers and served on editorial boards of multiple international journals. His contributions have received global recognition, including placement among the top 2% of scientists worldwide, multiple “Top Reviewer” honors from Publons, and numerous national research awards. Dr. Mehrpour’s work continues to elevate the fields of toxicology, predictive modeling, and precision medicine, contributing impactful solutions that improve healthcare systems and advance patient safety worldwide.

Profiles: Scopus | ORCID

Featured Publications

1. Eizadi-Mood, N., Barzam, E., Pirali, Z., Feizi, A., Namvar, M., Abdi, E., Mirmoghtadaee, P., Mehrpour, O., & Meamar, R. (2025). Gender differences in opioid and stimulant poisoning in the central region of Iran: A cross-sectional study. Scientific Reports.

2. Amrollahi-Sharifabadi, M., Oladejo, T. O., Ibrahim, A. S., Shakoor, B., Mehrpour, O., Sadeghi-Hashjin, G., & Gonçalves, S. (2025). Melatonin’s paradox: From therapeutic benefits to toxicity warnings. Chemico-Biological Interactions, 111556.

3. Kooshki, A., Mansouri, B., Farmani, R., Amirabadizadeh, A., Mehrpour, O., Sanjari, M. J., & Nakhaee, S. (2024). Essential and toxic metal concentrations in biological samples of multiple sclerosis patients: A systematic review and meta-analysis. PLOS ONE, 19(12), e0313851.

4. Mehrpour, O., & Sadeghi, M. (2024). The occurrence of unusually cold weather could contribute to the incidence of carbon monoxide poisoning. Clinical and Experimental Emergency Medicine.

5. Nakhaee, S., Kooshki, A., Hormozi, A., Akbari, A., Mehrpour, O., & Farrokhfall, K. (2023). Cinnamon and cognitive function: A systematic review of preclinical and clinical studies. Nutritional Neuroscience.

Sa Xiao | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Dr. Sa Xiao | Pharmaceutical Science | Best Researcher Award

Chief Pharmacist, Clinical pharmacist from The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, China

Sa Xiao is an experienced Clinical Pharmacist currently working at the Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China. she has dedicated her career to clinical pharmacy with a focus on providing quality patient care and optimizing pharmaceutical practices. Sa Xiao holds a Master’s degree in Pharmacology and a Bachelor’s degree in Pharmaceutical Engineering. Over the past five years and seven months, she has consistently contributed to clinical pharmacy, focusing on improving therapeutic outcomes and pharmaceutical interventions. Sa Xiao’s role places her at the intersection of clinical application and pharmaceutical research, where she works to enhance drug therapy effectiveness and patient safety. Her work contributes directly to hospital-based pharmaceutical care and supports interdisciplinary collaboration in medical settings. Sa Xiao’s background equips her with both theoretical knowledge and practical clinical experience, positioning her as a valuable asset in the healthcare system. While her current profile emphasizes her clinical expertise, expanding her research portfolio could further elevate her impact in the pharmaceutical field. Her dedication, professional growth, and potential for further research contributions make her a promising candidate for recognition in her domain.

Professional Profile

Education

Sa Xiao has built a strong academic foundation that supports her professional excellence in clinical pharmacy. She began her higher education journey at Huzhou Normal University, where she pursued a Bachelor’s degree in Pharmaceutical Engineering from September 2012 to June 2016. This program provided her with essential knowledge of pharmaceutical sciences, drug formulation, and pharmaceutical manufacturing processes. Her education at this stage focused on understanding drug properties, production, and the basic principles that guide pharmaceutical development. After completing her undergraduate studies, Sa Xiao advanced her academic qualifications by enrolling in Guangdong Medical University, where she earned her Master’s degree in Pharmacology from September 2016 to June 2019. This graduate program allowed her to delve deeper into the study of drug actions, mechanisms, and pharmacokinetics. Through her Master’s studies, she developed a comprehensive understanding of clinical pharmacology, which now directly supports her work as a clinical pharmacist. Both her degrees are recognized by the Ministry of Education, China, affirming the academic rigor and credibility of her educational background. Her academic journey demonstrates a seamless transition from pharmaceutical engineering to clinical application, providing her with the necessary expertise to excel in both pharmaceutical sciences and patient-centered clinical practice.

Professional Experience

Sa Xiao has gained substantial professional experience as a Clinical Pharmacist, holding this role since July 2019 at the Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology. With over five years of experience, she has developed a deep understanding of clinical pharmacy operations, patient care protocols, and hospital pharmaceutical services. Her responsibilities likely include reviewing prescriptions, optimizing medication therapies, ensuring the safe and effective use of drugs, and collaborating with medical teams to enhance patient outcomes. Working in a hospital affiliated with a reputable university has provided her with exposure to clinical research, medical education, and interdisciplinary cooperation. Sa Xiao’s experience is not limited to routine pharmacy tasks; her role also requires ongoing learning and adaptation to the latest pharmaceutical guidelines and therapeutic advancements. Her career has been characterized by dedication to improving patient care and supporting evidence-based clinical decisions. While her profile currently focuses on clinical responsibilities, there is potential for her to expand her contributions to include scientific publications, research studies, and leadership in pharmaceutical innovations. Her professional track record reflects commitment, consistency, and the ability to thrive in a demanding healthcare environment.

Research Interest

Sa Xiao’s research interests are rooted in clinical pharmacy and pharmacology, with a focus on optimizing drug therapies, enhancing patient safety, and improving pharmaceutical care within hospital settings. Her academic and professional background suggests a strong interest in therapeutic drug monitoring, drug interactions, and evidence-based medication management. She is likely driven to explore methods for improving the clinical efficacy of pharmacological treatments and minimizing adverse drug reactions. Additionally, she may be interested in research concerning personalized medicine, dosage adjustments for specific patient populations, and clinical outcomes related to pharmaceutical interventions. Her experience as a clinical pharmacist positions her to contribute valuable insights into hospital-based drug management, prescription review processes, and the practical challenges faced in clinical settings. Future research could also include comparative studies on the effectiveness of different pharmacological treatments and the implementation of clinical pharmacy protocols to improve patient care. By aligning her clinical expertise with focused research initiatives, Sa Xiao has the potential to contribute to both national and international discussions in the field of clinical pharmacology and pharmacy practice. Expanding her research interests to cover these areas would significantly strengthen her academic and professional profile.

Research Skills

Sa Xiao possesses a range of research skills that align with her clinical pharmacy background. Her academic training in pharmacology provided her with expertise in drug action mechanisms, pharmacokinetics, and pharmacodynamics, which are essential for conducting clinical pharmaceutical research. She likely has experience in analyzing clinical data, reviewing case studies, and evaluating therapeutic outcomes in real-world settings. Her role as a clinical pharmacist has refined her skills in prescription auditing, patient counseling, and drug therapy evaluation, which contribute to her ability to design practical, patient-focused research projects. Sa Xiao is also expected to be proficient in using clinical databases, medical literature review systems, and pharmacovigilance tools to support her clinical decision-making and potential research activities. Moreover, she may have developed collaborative skills through working with interdisciplinary teams, which are critical for conducting joint clinical studies and implementing hospital-wide pharmaceutical protocols. To further enhance her research portfolio, acquiring advanced skills in statistical analysis, research methodology, and scientific writing would be beneficial. By building on her current skill set and actively participating in research dissemination through conferences and publications, Sa Xiao can establish herself as a leading contributor in the clinical pharmacy research community.

Awards and Honors

At present, no specific awards or honors have been provided for Sa Xiao. However, her sustained commitment to clinical pharmacy over a period of more than five years at a leading university hospital reflects her professional reliability and growing expertise. Although formal recognitions such as research awards, clinical excellence distinctions, or academic honors have not yet been documented, Sa Xiao’s continuous role in a competitive healthcare environment signifies institutional trust in her capabilities. It is possible that she has received internal recognition for her contributions to patient care, medication management, or quality improvement initiatives within her department. Engaging in national or international pharmaceutical competitions, participating in recognized clinical research projects, and contributing to peer-reviewed publications could open avenues for future awards and honors. Earning formal recognition would not only validate her contributions but also help strengthen her professional profile for broader scientific and clinical acknowledgment. Sa Xiao’s consistent career growth and practical impact within the hospital setting suggest that she is well-positioned to achieve significant honors as she continues to expand her involvement in clinical research and professional development activities in the future.

Conclusion

In conclusion, Sa Xiao is a highly capable clinical pharmacist with a strong educational background and valuable experience in the hospital pharmaceutical sector. Her work at The Sixth Affiliated Hospital, School of Medicine, South China University of Technology demonstrates her ability to apply pharmacological knowledge in a clinical environment, directly benefiting patient care and therapeutic practices. While her current profile is predominantly clinical, there is significant potential for her to make substantial research contributions to the field of clinical pharmacy and pharmacology. Sa Xiao’s foundation in pharmaceutical engineering and pharmacology equips her with both theoretical and practical expertise, which can be further advanced through scientific publications, conference presentations, and research collaborations. By actively participating in research dissemination and seeking broader recognition through professional awards, she can enhance her influence within the scientific and medical communities. Sa Xiao’s dedication, clinical precision, and future research potential position her as an emerging contributor to the advancement of pharmaceutical care and clinical pharmacy research. With further academic engagement and research output, she is likely to achieve greater professional recognition and make impactful contributions to the global healthcare landscape.

Publications Top Notes

1. Depression and Suicide/Self-Injury Signals for Weight Loss Medications: A Disproportionality Analysis of Semaglutide, Liraglutide, and Tirzepatide in FAERS Database

  • Journal: Journal of Affective Disorders

  • Publication Date: 2025-06-14

  • Authors: Wang M, Yang Z, Yan M, Liu S, Xiao S

2. Protective Effects of Aqueous Extract of Wampee Fruit Against Anti-Tubercular Drug-Induced Hepatotoxicity in Rats

  • Journal: Journal of Biological Regulators and Homeostatic Agents

  • Publication Date: 2019-01-01

  • Authors: Guan TM, Xiao S, Liu DC, Liao XH, Li WD, Wu KF, Huang R

 

Phuong Linh Ta | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Ms. Phuong Linh Ta | Pharmaceutical Science | Best Researcher Award

University CEU CArdenal Herrera, Spain

Phuong Linh Ta is an emerging researcher in the field of pharmacology, currently pursuing her doctoral studies at Universidad Cardenal Herrera CEU in Spain. She is a highly motivated scientist with a solid academic foundation and practical experience in pharmaceutical research, particularly focusing on ocular drug delivery systems and antibiotic discovery. Throughout her career, she has actively contributed to impactful projects that address pressing global health concerns, such as the development of new antibiotics and the prevention of cognitive decline associated with diseases like Alzheimer’s. She has consistently demonstrated a passion for contributing to both scientific advancement and community well-being through her involvement in various outreach programs including elderly care and sustainable development challenges. Phuong Linh Ta’s scientific journey is marked by a balanced integration of academic excellence, innovative research, and social engagement. Her participation in prestigious conferences across Europe has allowed her to present her work to the international scientific community, thereby expanding her professional network and research visibility. With her commitment to continuous learning, interdisciplinary collaboration, and practical applications in the pharmaceutical field, Phuong Linh Ta is steadily building a robust research portfolio that holds promise for future breakthroughs in pharmacology and clinical applications.

Professional Profile

Education

Phuong Linh Ta’s educational background showcases a steady progression in pharmaceutical sciences and clinical research. She completed her Master’s degree in Direction and Monitorization of Clinical Trials from Universidad Cardenal Herrera CEU in 2022, equipping her with specialized knowledge in clinical trial design and pharmaceutical study management. Prior to that, she earned her Bachelor’s degree in Pharmacy from the same university in 2021, which provided her with a strong foundation in pharmacological principles, drug formulation, and patient care. She also participated in the Forster Summer School at the University of Mainz in 2019, where she gained international exposure and broadened her academic perspective. Her early academic journey includes completing the International Baccalaureate at Birkerød Gymnasium, HF, IB & Boarding School in Denmark, which highlights her global educational experience. This diverse and international academic pathway has given her a broad cultural and scientific outlook, enhancing her adaptability and communication across different educational and professional environments. Her formal education has been consistently aligned with her research interests, particularly in clinical pharmacology, drug delivery systems, and public health, positioning her well for her doctoral research and future contributions to the pharmaceutical sector.

Professional Experience

Phuong Linh Ta has developed substantial professional experience through various academic roles at Universidad Cardenal Herrera CEU. She is currently engaged as a doctoral student in the Faculty of Pharmacy, focusing on pharmacology research, with her work beginning in November 2022. Her previous roles include serving as a Pharmacy Classroom Assistant, where she provided educational support and facilitated learning for undergraduate students. Additionally, she worked as an Internal Student in the Department of Pharmacology, where she honed her laboratory and research skills through hands-on involvement in pharmaceutical studies. Her collaborative roles in the departments of Languages and Communication further enriched her interpersonal, administrative, and organizational capabilities, demonstrating her versatility and commitment to contributing to different facets of the university environment. These experiences have provided her with a well-rounded understanding of both research and academic operations, preparing her for independent and collaborative work in complex scientific projects. Her sustained professional engagement within the same institution illustrates her reliability, long-term dedication, and growth within the academic community. Her evolving responsibilities have enabled her to build a solid foundation in both teaching and research, setting the stage for her continued contributions to the field of pharmacology.

Research Interest

Phuong Linh Ta’s primary research interests lie at the intersection of pharmacology, drug delivery systems, and clinical applications aimed at improving patient outcomes. She is particularly focused on the development of ocular drug delivery platforms, including the formulation and characterization of ocular inserts to enhance the bioavailability and targeted release of therapeutic agents. Her recent research has concentrated on using alpha-lipoic acid in beta-cyclodextrin complexes for improved delivery to the posterior segment of the eye, which holds significant potential for the treatment of ocular diseases and the prevention of long-term complications associated with high myopia. Additionally, she has been involved in projects that address global health challenges such as the discovery of new antibiotics and the promotion of their rational use, aligning her work with the global fight against antimicrobial resistance. Her interest extends to neuroprotective strategies for the early prevention of cognitive deterioration, reflecting her multidisciplinary approach that bridges pharmaceutical technology with public health priorities. Phuong Linh Ta’s research is deeply rooted in translating laboratory findings into practical healthcare solutions, and she is committed to advancing drug delivery science to make therapeutics more efficient, accessible, and patient-centered.

Research Skills

Phuong Linh Ta possesses a diverse range of research skills that are crucial to her contributions in pharmaceutical sciences. She is proficient in developing and characterizing drug delivery systems, particularly ocular inserts, and has significant experience in in vitro release studies and ex vivo diffusion studies. Her technical expertise includes working with complex molecular assemblies like beta-cyclodextrin complexes, optimizing drug stability and bioavailability. She is skilled in conducting clinical trials, managing pharmacological experiments, and applying service-learning methodologies in educational and research settings. Her involvement in competitive R&D projects has also equipped her with skills in project planning, data analysis, and scientific reporting. Furthermore, she has effectively communicated her research findings at multiple international conferences, indicating her capability in scientific presentation and knowledge dissemination. Phuong Linh Ta’s multilingual abilities—fluency in Vietnamese, Spanish, and English—further enhance her collaborative potential in diverse research environments. Her capacity to integrate laboratory research with clinical applications and her aptitude for both independent and team-based work make her a versatile and competent researcher. She continuously seeks to refine her laboratory techniques, analytical skills, and knowledge of pharmacological systems to remain at the forefront of her field.

Awards and Honors

As of the current stage of her career, Phuong Linh Ta’s recognition is primarily reflected in her selection for multiple competitive research projects and her invitations to present at prestigious scientific conferences across Europe. She has actively participated in national and international conferences such as EVER, the Controlled Release Society (CRS) Annual Meeting, and the Spanish-Portuguese Conference on Controlled Drug Delivery. These platforms have provided her with opportunities to showcase her research and gain valuable feedback from global experts. Her consistent involvement in the SWI@CEU project and the DeCo MICOF-CEU project demonstrates the trust her academic institution places in her research capabilities. While she has not yet accumulated formal awards or fellowships, her current academic track record and research engagement highlight her potential for future recognition and academic distinction. Participation in such competitive and high-impact research initiatives serves as an important professional milestone, indicating her emerging status within the scientific community. Moving forward, continued success in publishing peer-reviewed articles and leading independent research projects will likely pave the way for her to receive more significant awards, grants, and honors that will further validate her contributions to pharmaceutical sciences.

Conclusion

Phuong Linh Ta is a dedicated and promising researcher who has steadily built a strong foundation in pharmacology and pharmaceutical research through her education, professional experience, and focused scientific contributions. Her work reflects a commitment to developing innovative drug delivery systems, with particular emphasis on ocular therapeutics and public health impact. While her research is still in the early stages, she has already gained substantial international exposure and actively contributed to community-based and service-learning projects. Her technical skills, multilingual proficiency, and ability to collaborate in multidisciplinary teams make her well-prepared to take on more advanced research challenges in the future. Although there are areas for growth, especially in peer-reviewed publications and leadership of independent projects, her trajectory suggests she is on the right path toward becoming a highly impactful researcher. With further development and continued dedication, Phuong Linh Ta has the potential to significantly contribute to advancements in drug delivery, pharmacology, and patient-centered healthcare solutions. Her work is aligned with global health priorities, and she is well-positioned to make meaningful scientific contributions in both academic and clinical contexts.

Publications Top Notes

  • Title: Optimization and Validation of a High‐Performance Liquid Chromatography (HPLC‐UV) Method for Quantification of α‐Lipoic Acid in Cyclodextrins Complex for Ocular Delivery

  • Authors: Phuong Linh Ta, Lucia Bernat‐Just, Adrián M. Alambiaga‐Caravaca, Vicent Rodilla, Alicia López‐Castellano, Francisco Bosch‐Morell

  • Year: 2025

Yongpan An | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Dr. Yongpan An | Pharmaceutical Science | Best Researcher Award

Pharmacology Researcher from Xi’an People’s Hospital (Xi’an Fourth Hospital), China

Yongpan An is an emerging researcher in the field of pharmacology, specializing in drug screening and the mechanistic study of aging and aging-related diseases. A recent Ph.D. graduate from Peking University, Dr. An has demonstrated significant promise through his contributions to high-impact research, authoring and co-authoring several peer-reviewed publications. His work spans various disciplines, including molecular biology, artificial intelligence, and pharmacological intervention, reflecting a multidisciplinary approach essential for innovative biomedical research. As of now, he is affiliated with Xi’an People’s Hospital, where he continues to build on his doctoral research. Dr. An has already co-authored influential studies published in journals such as Nature Biotechnology, Aging Cell, Frontiers in Pharmacology, and Life Medicine. Despite being early in his career, his scientific output, collaboration with renowned researchers, and peer review responsibilities signal a strong foundation for a successful academic trajectory. His research addresses a critical area in medical science—aging—and aims to identify compounds that can prolong lifespan and reduce age-associated degeneration. With demonstrated leadership in co-authorship roles and contributions to the understanding of pharmacological interventions for aging, Yongpan An stands out as a dedicated, capable, and innovative young scientist poised for further accomplishments.

Professional Profile

Education

Yongpan An’s academic journey reflects a solid foundation in biotechnology and pharmacology, cultivated through rigorous training at leading Chinese institutions. He began his undergraduate studies in Biotechnology at Yunnan University, where he developed fundamental skills in molecular biology and biochemical research. From 2014 to 2018, he was immersed in coursework and research that exposed him to laboratory techniques and foundational knowledge in life sciences. His pursuit of advanced studies led him to Peking University, one of China’s most prestigious academic institutions, where he obtained his Ph.D. in Pharmacology between 2018 and 2023. At Peking University, under the mentorship of Dr. Zhengwei Xie, he focused on drug screening and the molecular mechanisms underlying aging. During this period, Dr. An gained hands-on experience with advanced pharmacological methodologies, contributing to several high-impact studies. His doctoral training not only equipped him with scientific expertise but also fostered skills in critical thinking, interdisciplinary collaboration, and scientific communication. His research incorporated cutting-edge areas such as the application of artificial intelligence in drug discovery, reinforcing the modern relevance of his education. This academic progression—from biotechnology to pharmacology—provides a robust framework for his current and future research endeavors in aging and age-related diseases.

Professional Experience

Dr. Yongpan An is currently employed at Xi’an People’s Hospital, where he continues to engage in pharmacological research with a focus on aging and age-related diseases. Although early in his professional career, Dr. An has already demonstrated remarkable productivity and leadership in scientific research. During his doctoral studies at Peking University, he was deeply involved in collaborative projects that combined pharmacological experimentation with computational analysis. His work involved both in vivo and in vitro models, providing him with experience across various experimental platforms. In addition to research responsibilities, Dr. An served as a reviewer for the journal Pharmacological Research, evaluating scientific manuscripts and gaining familiarity with the editorial and peer-review process. His professional engagements have also included active participation in scientific conferences and forums, where he presented his findings and interacted with experts in the field of aging and pharmacology. Notably, he played a major role in authoring a comprehensive review titled The Landscape of Aging, where he was responsible for summarizing the application of artificial intelligence in anti-aging drug discovery. As he transitions from a student to an independent researcher, Dr. An continues to demonstrate commitment to excellence, innovation, and scientific rigor in his ongoing professional endeavors.

Research Interests

Dr. Yongpan An’s primary research interests lie in the pharmacological modulation of aging and the discovery of novel compounds targeting aging-related diseases. His work integrates drug screening techniques with the mechanistic study of cellular and organismal aging processes. Specifically, he is interested in understanding how small molecules interact with key molecular pathways, such as the AKT signaling cascade, p16, and cyclin regulatory mechanisms, to delay senescence and promote healthy lifespan extension. Another key area of interest for Dr. An is the use of natural products, such as oridonin and berberine, in regulating cellular aging. His contributions to this field are evident from his publications in high-impact journals that explore the therapeutic potential of such compounds in mouse and yeast models. Additionally, he has contributed to the development of AI-driven tools for predicting drug efficacy from transcriptional profiles, showcasing his interest in computational pharmacology. The integration of artificial intelligence and deep learning with experimental pharmacology highlights his vision of combining traditional experimental approaches with cutting-edge digital methodologies. His overarching goal is to discover and validate compounds that not only extend lifespan but also improve quality of life by mitigating the effects of chronic and degenerative diseases associated with aging.

Research Skills

Dr. Yongpan An possesses a diverse and interdisciplinary set of research skills, developed through years of academic training and hands-on laboratory experience. He is proficient in a wide range of pharmacological and molecular biology techniques, including cell culture, Western blotting, immunofluorescence, RNA extraction, and quantitative PCR. He has extensive experience working with animal models, especially in the context of lifespan and senescence studies in mice and yeast, which are central to his research in aging. His capabilities also include the screening and identification of bioactive compounds using high-throughput methods, allowing him to evaluate the pharmacodynamic and pharmacokinetic properties of candidate molecules. Dr. An is adept at using bioinformatics and artificial intelligence tools to analyze gene expression data and predict drug responses. This skillset was crucial in his involvement in the development of deep learning models for drug efficacy prediction, published in Nature Biotechnology. Moreover, his experience as a peer reviewer reflects his ability to critically assess scientific literature and evaluate experimental design, data quality, and interpretation. His collaborative skills and familiarity with interdisciplinary projects further enhance his research capabilities, making him an asset to both academic and clinical research teams focusing on anti-aging pharmacological interventions.

Awards and Honors

Despite being at the beginning of his career, Dr. Yongpan An has already received several prestigious awards in recognition of his academic excellence and research achievements. During his doctoral studies at Peking University, he was honored with the National Scholarship, a highly competitive award given to outstanding students in China. He also received the First Prize in the Soaring Young Scholar competition held by Northwestern Polytechnical University, which recognizes young researchers for innovative scientific contributions. Additionally, he was awarded the Second Prize at the Young Scientist Forum Report organized by the Beijing Society of Pharmacology and Physiological Sciences, affirming his potential as a promising figure in pharmacological research. These honors not only reflect his dedication to scientific inquiry but also underscore the impact and relevance of his work within the research community. His involvement as a co-first author in significant collaborative publications further demonstrates peer recognition of his scholarly efforts. Beyond awards, his service as a manuscript reviewer for an established journal like Pharmacological Research highlights the trust placed in his scientific judgment. Collectively, these accolades validate Dr. An’s emerging role as a capable and committed young scientist with a promising future in pharmacology and aging research.

Conclusion

In summary, Dr. Yongpan An embodies the qualities of a highly promising early-career researcher with a strong academic foundation, impactful research output, and growing recognition within the scientific community. His work focuses on one of the most critical areas in medical science—understanding and intervening in the aging process to improve human health and longevity. His background in both experimental pharmacology and artificial intelligence places him at the intersection of innovation and translational medicine. Despite his relatively recent graduation, he has already authored multiple first-author publications, participated in high-level collaborative research, and received awards for his contributions. Dr. An’s dedication to advancing the pharmacological understanding of aging-related diseases and his proactive engagement in academic publishing and peer review highlight his scientific maturity. He is currently well-positioned to expand his research, attract future funding, and lead independent projects that will further enhance his professional profile. As he continues to build his research portfolio at Xi’an People’s Hospital, Dr. An is likely to contribute significantly to the development of therapeutic strategies that target aging and its associated disorders. Therefore, he represents an outstanding candidate for recognition through awards that honor excellence in scientific research.

Publications Top Notes

  1. Title: Genetically modified extracellular vesicles loaded with activated gasdermin D potentially inhibit prostate-specific membrane antigen-positive prostate carcinoma growth and enhance immunotherapy
    Authors: Gao, Ke; Xi, Wenjin; Ni, Jianxin; Zhang, Rui; Wu, Guojun
    Journal: Biomaterials
    Year: 2025

Carolina Batista | Pharmaceutical Science | Women Researcher Award

Published on by World Science Awards

Dr. Carolina Batista | Pharmaceutical Science | Women Researcher Award

Biomedical from Federal University of Rio de Janeiro, Brazil

Dr. Carolina Batista is a distinguished global health physician with over two decades of experience in humanitarian and public health initiatives. Currently serving as the Head of Global Health Affairs at Baraka Impact Finance, she leverages her medical expertise and strategic insight to foster innovative health solutions for underserved populations. Her career commenced in Brazil, where she provided medical care to indigenous communities in the Amazon. In 2007, she joined Médecins Sans Frontières (MSF), undertaking assignments in Somalia, Africa, and Latin America, focusing on neglected tropical diseases (NTDs) and emerging infectious diseases. As Director of MSF’s Brazilian Medical Unit, she led international campaigns, notably for Chagas disease. Subsequently, at the Drugs for Neglected Diseases initiative (DNDi), she spearheaded access frameworks for NTDs across Latin America, influencing public policies and fostering partnerships. Dr. Batista holds a medical degree from Brazil and a master’s in International Public Health from institutions including the Swiss Tropical and Public Health Institute. Her contributions extend to roles on the International Board of MSF, The Lancet COVID-19 Commission, and as a strategic advisor for ISGlobal, reflecting her commitment to health equity and innovation in global health.

Professional Profile

Education

Dr. Carolina Batista’s educational journey is marked by a blend of clinical training and global public health expertise. She earned her medical degree in Brazil, grounding her in clinical practice and primary healthcare delivery. Pursuing a broader impact, she obtained a master’s degree in International Public Health through a collaborative program involving the Swiss Tropical and Public Health Institute, the Institute of Tropical Medicine in Antwerp, and the Royal Tropical Institute in Amsterdam. This multidisciplinary education equipped her with a comprehensive understanding of global health challenges, particularly in infectious and neglected diseases. Further enhancing her capabilities, Dr. Batista pursued advanced studies in management, health and human rights, and policy and advocacy from renowned institutions. This diverse educational background has been instrumental in her ability to design and implement effective health interventions and policies across various international contexts.

Professional Experience

Dr. Carolina Batista’s professional trajectory encompasses significant roles in global health organizations. Her career began in Brazil, providing medical care to indigenous communities in the Amazon. In 2007, she joined Médecins Sans Frontières (MSF), undertaking assignments in Somalia and later serving as Director of the Brazilian Medical Unit, focusing on neglected tropical diseases (NTDs) and emerging infectious diseases. She led international campaigns, notably for Chagas disease, and coordinated MSF’s medical response to COVID-19 in the Navajo Nation, USA. At the Drugs for Neglected Diseases initiative (DNDi), she served as Head of Access and Medical Affairs, developing access frameworks for NTDs across Latin America. Currently, as Head of Global Health Affairs at Baraka Impact Finance, she supports social entrepreneurs in developing innovative health solutions. Dr. Batista also holds positions on the International Board of MSF and serves as a strategic advisor for ISGlobal

Research Interests

Dr. Carolina Batista’s research interests are deeply rooted in global health equity, focusing on neglected tropical diseases (NTDs), health systems in low- and middle-income countries, and access to healthcare for vulnerable populations. She is particularly interested in the development and implementation of innovative financing mechanisms to achieve the Sustainable Development Goals (SDGs), the role of private capital in bridging healthcare access gaps, and the integration of ethical artificial intelligence in health communication. Her work also explores the intersection of migration and health, pandemic preparedness, and the gender gap in healthcare access. Dr. Batista’s research aims to inform policies and practices that enhance healthcare delivery and accessibility for marginalized communities worldwide.

Research Skills

Dr. Carolina Batista possesses a robust set of research skills that encompass both qualitative and quantitative methodologies. Her expertise includes treatment protocols, health systems analysis, diagnostics, and primary care, particularly concerning parasitic and neglected diseases. She is adept at designing and implementing operational research projects, developing access frameworks, and conducting policy analysis. Her skills extend to evaluating health programs, engaging with stakeholders, and advocating for policy changes. Dr. Batista’s proficiency in these areas enables her to contribute effectively to research initiatives aimed at improving health outcomes in underserved populations.

Awards and Honors

Dr. Carolina Batista’s contributions to global health have been recognized through various appointments and memberships. She serves on the International Board of Médecins Sans Frontières (MSF) and is a strategic advisor for the Barcelona Institute for Global Health (ISGlobal). Her role in leading MSF’s medical response to COVID-19 in the Navajo Nation and her involvement in The Lancet COVID-19 Commission underscore her commitment to addressing health crises. Additionally, she chairs the DNDi Latin America board and serves on the boards of The Lancet Migration Latin America, Movement Health Foundation, and Health in Harmony. These positions reflect her leadership and dedication to advancing health equity and innovation.

Conclusion

Dr. Carolina Batista exemplifies a career dedicated to advancing global health equity through clinical practice, research, and policy development. Her extensive experience with organizations like MSF and DNDi, coupled with her strategic role at Baraka Impact Finance, highlights her commitment to improving healthcare access for marginalized populations. Her educational background and research interests inform her holistic approach to health challenges, integrating innovative solutions with traditional practices. Dr. Batista’s leadership roles and board memberships further demonstrate her influence in shaping global health policies and initiatives. Her work continues to inspire and drive progress towards equitable healthcare worldwide.

Publications Top Notes

1. Exposed Subsoil Under Recovery for 30 Years: Influence of Management Strategies on Soil Physical Attributes and Organic Matter

  • Authors: Laura Silva Nantes, Carolina dos Santos Batista Bonini, Melissa Alexandre Santos, Lucas da Silva Alves, Josiane Lourencetti, Alfredo Bonini Neto, José Augusto Liberato de Souza, Gabriel Augusto da Silva Lunardelli, Mariana Bonini Silva, Dayara Vivian Alvares, et al.

  • Year: 2025

2. Accumulated Carbon Fractions in Tropical Sandy Soils and Their Effects on Fertility and Grain Yield in an Integrated Crop–Livestock System

  • Authors: Deyvison de Asevedo Soares, Bianca Midori Souza Sekiya, Viviane Cristina Modesto, Allan Hisashi Nakao, Leandro Alves Freitas, Isabela Malaquias Dalto de Souza, J.H.S. Luz, Fernando Shintate Galindo, Gelci Carlos Lupatini, Gustavo Pavan Mateus, et al.

  • Year: 2023

3. Evolution of Soil Chemical Fertility in an Area under Recovery for 30 Years with Anthropic Intervention

  • Authors: Josiane Lourencetti, Carolina dos Santos Batista Bonini, Marcelo Andreotti, Marlene Cristina Alves, Alfredo Bonini Neto, Melissa Alexandre Santos, Vitor Correa de Mattos Barretto, Roberth Wicleff Rodrigues de Figueredo

  • Year: 2023

4. Long-Term Integrated Systems of Green Manure and Pasture Significantly Recover the Macrofauna of Degraded Soil in the Brazilian Savannah

  • Authors: Carolina dos Santos Batista Bonini, Thais Monique de Souza Maciel, Bruno Rafael de Almeida Moreira, José Guilherme Marques Chitero, Rodney Lúcio Pinheiro Henrique, Marlene Cristina Alves

  • Year: 2023

5. Long-Term Integrated Crop–Livestock–Forestry Systems Recover the Structural Quality of Ultisol Soil

  • Authors: Aline Matos, Carolina dos Santos Batista Bonini, Bruno Rafael de Almeida Moreira, Marcelo Andreotti, Reges Heinrichs, Diogo Tiago da Silva, José Augusto Liberato de Souza, Melissa Alexandre Santos, Cristiana Andrighetto, Gustavo Mateus Pavan, et al.

  • Year: 2022

6. Azospirillum Inoculation of ‘Marandu’ Palisade Grass Seeds: Effects on Forage Production and Nutritional Status

  • Authors: Reges Heinrichs, G.C. Meirelles, L.F. de Melo Santos, M.V. da Silva Lira, A. de Marcos Lapaz, M.A. Nogueira, C. dos Santos Batista Bonini, Filho, A. Moreira

  • Year: 2020

7. Can Palisade and Guinea Grass Sowing Time in Intercropping Systems Affect Soybean Yield and Soil Chemical Properties?

  • Authors: N.R. Costa, Marcelo Andreotti, C.A.C. Crusciol, C.M. Pariz, J.W. Bossolani, A.M.D. Castilhos, C.A.C.D. Nascimento, C.G.D.R. Lima, C. dos Santos Batista Bonini, E.E. Kuramae

  • Year: 2020

8. Effect of Sulfur Sources on Megathyrsus Maximus ‘Mombaça’ Grass Cultivated in a Typic Ultisol

  • Authors: L.F. de Melo Santos, A. de Marcos Lapaz, F.V. Ribeiro, I.V. Ribeiro, G.C. Meirelles, M.V. da Silva Lira, C.V. Soares Filho, C. dos Santos Batista Bonini, A.R. dos Reis, A. Moreira, et al.

  • Year: 2020

9. Soil Compaction in Crop-Livestock-Forest Integration Systems of Five Years of Implantation and Use

  • Authors: J.F.D. Souza, C. dos Santos Batista Bonini, G.P. Mateus, C.T. de Souza, R.L.S. Perusso, F.G. Pedro, G.L. Oliverio

  • Year: 2020

10. Spray Nozzles and Droplet Size Effects on Soybean Canopy Deposits and Stink Bugs Control in West Region of São Paulo State – Brazil

  • Authors: M.A.G.L. Farias, C.G. Raetano, R.G. Chechetto, P.J. Ferreira-Filho, J.C. Guerreiro, C.S.B. Bonini, A.C. Firmino, R.C. Lima, E.P. Prado

  • Year: 2020

​






	


	

	






	
	

		


Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award
			

				Published on  by World Science Awards			

		
	


	

		
Assoc. Prof. Dr. Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award


Associate Professor from Department of Physiology, China Medical University, Taiwan




















Yi-Ping Huang is an accomplished Associate Professor in the Department of Physiology at China Medical University, with over 32 years of experience in both teaching and research. His primary focus is on cancer treatment, specifically investigating the therapeutic effects of natural and synthetic compounds on cancer cells. Over the years, Huang has significantly contributed to the field, publishing numerous peer-reviewed articles and advancing the understanding of cancer treatment mechanisms, particularly apoptosis, DNA damage, and anti-metastasis pathways. His expertise extends to drug synergy, especially in combination with chemotherapy. He has also been involved in teaching innovations in physiology, emphasizing student engagement and educational research. Huang’s extensive research output and leadership in the field have made him a well-respected figure in the scientific community, as reflected in his numerous research projects and academic publications.


Professional Profile



Education


Yi-Ping Huang completed his undergraduate studies in Physiology at Yang-Ming University, laying the foundation for his extensive career in research and academia. His academic journey provided a strong base for his research into cancer treatment and physiological mechanisms. This solid educational background enabled Huang to develop expertise in a range of specialized topics, particularly in the therapeutic effects of natural compounds. Over the years, his continuous learning and commitment to his field have propelled his success, making him an established academic in the study of cancer therapy and physiology.


Professional Experience


Yi-Ping Huang has a long and distinguished career in both academia and research. As an Associate Professor at China Medical University, he has been instrumental in educating students and conducting cutting-edge research on cancer therapy. With over three decades of experience, Huang has led numerous research projects focusing on natural and synthetic compounds in cancer treatment. His role also includes teaching and mentoring students, guiding them in the latest scientific advancements. Huang’s professional experience is marked by extensive publications in high-impact journals, further showcasing his contributions to the scientific community and his leadership in advancing cancer research.


Research Interests


Yi-Ping Huang’s primary research interests revolve around the use of natural and synthetic compounds in cancer therapy. His work explores the mechanisms through which these compounds induce apoptosis, DNA damage, and inhibit metastasis in cancer cells. Huang is particularly focused on understanding how these compounds can synergize with chemotherapy drugs to overcome resistance and improve treatment outcomes. His ongoing research also investigates the therapeutic effects of compounds such as Demethoxycurcumin (DMC), Phenethyl Isothiocyanate (PEITC), and PW06 in various cancer types, including glioblastoma and colon cancer. These areas of interest align with his goal of advancing cancer therapy through the identification and development of novel therapeutic agents.


Research Skills


Yi-Ping Huang’s research skills are extensive and diverse, ranging from molecular biology techniques to cancer therapy research. He possesses a deep understanding of cancer cell biology, particularly in apoptosis, DNA repair, and metastasis inhibition. Huang has demonstrated proficiency in the use of various experimental models to study the effects of natural and synthetic compounds on cancer cells, including in vitro and in vivo models. His expertise extends to studying drug interactions and mechanisms of drug resistance, especially in relation to chemotherapy. Huang’s interdisciplinary approach to research, combining pharmacology, molecular biology, and cancer therapy, has led to groundbreaking studies that have contributed significantly to the field.


Awards and Honors


Throughout his illustrious career, Yi-Ping Huang has received numerous awards and honors that recognize his contributions to the scientific community. His groundbreaking research in cancer therapy, particularly in the use of natural and synthetic compounds, has earned him accolades from academic institutions and scientific organizations. Huang’s work on compounds such as Demethoxycurcumin and Phenethyl Isothiocyanate has been widely recognized in the field of oncology research. His consistent contributions to cancer treatment research and his leadership in academia have earned him recognition as a leading expert in his field, enhancing his reputation as an influential figure in cancer research.


Conclusion


Yi-Ping Huang’s career has been defined by significant contributions to cancer research, particularly in the development and understanding of natural and synthetic compounds as therapeutic agents. His research focuses on the molecular mechanisms of apoptosis, DNA damage, and anti-metastasis, offering potential for groundbreaking advancements in cancer treatment. With over three decades of experience, Huang’s work continues to influence both basic and clinical cancer research. His leadership in academia, coupled with his innovative research, positions him as a respected figure in the scientific community. As he continues to push the boundaries of cancer therapy, his contributions are likely to have a lasting impact on the field.


Publication Top Notes


M084 causes cell cycle arrest and inhibits voltage-gated Na⁺ and K⁺ channels in neuronal N2A cells
Authors: Iat Lon Leong, Chinmin Chuang, Chenghsun Wu, Yukman Leung, Yiping Huang
Year: 2025


2. MCU-i4, a mitochondrial Ca²⁺ uniporter modulator, induces breast cancer BT474 cell death by enhancing glycolysis, ATP production and reactive oxygen species (ROS) burst
Authors: Edmund Cheung So, Louis Wing Cheong Chow, Chinmin Chuang, Yukman Leung, Yiping Huang
Year: 2025


3. Physalin A induces apoptosis through conjugating with Fas-FADD cell death receptor in human oral squamous carcinoma cells and suppresses HSC-3 cell xenograft tumors in NOD/SCID mice
Authors: Fu Shin Chueh, Shengyao Hsu, Kuangchi Lai, Yiping Huang, Wen Tsong Hsieh
Year: 2025


4. PEITC Induces DNA Damage and Inhibits DNA Repair-Associated Proteins in Human Retinoblastoma Cells In Vitro
Authors: Shengyao Hsu, Yiping Huang, Techun Hsia, Fu Shin Chueh, Chaolin Kuo
Year: 2024


5. Armillaria mellea Mycelia Alleviate PM2.5-Induced Pulmonary Inflammation in Murine Models
Authors: Yiping Huang, Yutsen Huang, Huiyu Wu, Chinchu Chen, Chih Ho Lai
Year: 2024


6. RAGE participates in the intracellular transport of Campylobacter jejuni cytolethal distending toxin
Authors: Yufang Chang, Yiping Huang, Chiahuei Chou, Chenghsun Chiu, Chih Ho Lai
Year: 2024
Citations: 2


7. PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa-2 cells via the inhibitions of p-Akt/mTOR/NF-κB and MMP2/MMP9 signaling pathways in vitro
Authors: Yiping Huang, Chunan Yeh, Yishih Ma, Jin Cherng Lien, Wen Tsong Hsieh
Year: 2024
Citations: 2